Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches

Amos J de Jong, Mira G P Zuidgeest, Yared Santa-Ana-Tellez, Anthonius de Boer, Helga Gardarsdottir*,

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Methodological and operational clinical trial innovation is needed to address key challenges associated with clinical trials, including limited generalizability and (s)low recruitment rates. In this article, we discuss how appropriate implementation of innovative clinical trial approaches can be facilitated by a timely identification of, and response to, emerging situations and innovation by regulators (i.e. regulatory readiness) using decentralized clinical trial (DCT) approaches - in which trial activities are moved closer to participants and away from the investigative sites - as a case study example. Specifically, we discuss how explorative research (e.g. using regulatory sandboxes) can enable the collection of data on the usefulness of DCT approaches. Additionally, we argue that DCT approaches should be evaluated similarly to conventional clinical trials.

Original languageEnglish
Article number104180
Number of pages8
JournalDrug Discovery Today
Volume29
Issue number11
Early online date14 Sept 2024
DOIs
Publication statusPublished - Nov 2024

Keywords

  • clinical trial innovation
  • decentralized clinical trials
  • regulation
  • regulatory readiness
  • regulatory science

Fingerprint

Dive into the research topics of 'Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches'. Together they form a unique fingerprint.

Cite this